Cytokinetics (NASDAQ: CYTK) — Company Overview, News & Financial Data
Cytokinetics is a biopharmaceutical company developing muscle activators and inhibitors for heart and skeletal diseases.
Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases characterized by compromised muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company focuses on cardiovascular and neuromuscular diseases, including hypertrophic cardiomyopathy, heart failure, and amyotrophic lateral sclerosis. Its clinical pipeline leverages expertise in muscle biology to target cardiac and skeletal muscle motor proteins, advancing novel small molecule drug candidates aimed at improving patient muscle performance and clinical outcomes.
Snapshot
Operations
Products and/or services of Cytokinetics
- Cardiac Myosin Inhibitors: An investigational, selective small molecule therapy designed to reduce myocardial hypercontractility in patients with obstructive hypertrophic cardiomyopathy, supported by pivotal Phase 3 clinical trials including SEQUOIA-HCM and MAPLE-HCM.
- Cardiac Myosin Activators: A novel, selective small molecule designed to improve cardiac muscle performance and increase systolic ejection duration in patients living with heart failure with reduced ejection fraction by targeting cardiac myosin directly.
- Cardiac Troponin Activators: A selective small molecule agent designed to enhance cardiac contractility through a distinct mechanism of action, increasing myocardial calcium sensitivity for the potential treatment of severe heart failure and impaired ventricular function.
- Skeletal Muscle Activators: Research and development programs focusing on novel fast skeletal muscle troponin activators intended to improve skeletal muscle function, physical capacity, and performance in patients affected by debilitating neuromuscular conditions such as amyotrophic lateral sclerosis.
- Next-Generation Cardiac Inhibitors: An investigational, selective small molecule therapy engineered to address specific physiological requirements and therapeutic windows in patients diagnosed with non-obstructive hypertrophic cardiomyopathy and related cardiovascular disorders.
- Muscle Biology Discovery Engine: A specialized research platform utilizing structural biology, high-throughput biophysical assays, and automated cellular models to identify and optimize novel small molecule modulators targeting cardiac and skeletal muscle motor proteins.
Cytokinetics executive team
- Mr. Robert I. BlumCEO, President & Director
- Mr. Sung H. LeeEVP & CFO
- Dr. Fady Ibraham Malik FACC, M.D., Ph.D.Executive Vice President of Research & Development
- Mr. Andrew M. CallosExecutive VP & Chief Commercial Officer
- Dr. James A. Spudich Ph.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Jeff LotzVice President of Sales & Operations
- Ms. Holly LaughlinVP of Accounting & Corporate Controller
- Mr. Steven M. Cook J.D.Senior Vice President of Global Supply Chain Operations & Technical Operations
- Mr. Jeffrey J. Hessekiel J.D.Executive VP, Chief Legal & Administrative Officer
- Ms. Kari K. Loeser J.D.VP & Chief Compliance Officer